David F. Chang
WASHINGTON — Data from the COMPARE trial for the Hydrus microstent vs. two iStents as a stand-alone treatment for open-angle glaucoma showed some advantages for the Hydrus, according to a speaker here.
“In the comparison, Hydrus was statistically superior in lowering the medication count, the number of eyes that were completely medication free at a year, the number of eyes in terms of preventing them from requiring three or more medications, and then in addition reducing the IOP by an additional 20%,” David F. Chang, MD, said (Read more...)
Uncategorized